Congress orders Pentagon to study psilocybin for veteran PTSD
H.R. 9547 — Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026 · Filed by Abraham Hamadeh (R-AZ) · 4 cosponsors · Introduced Jun 30, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Defense to review clinical trial data on psilocybin-containing mushrooms as a potential treatment for treatment-resistant PTSD in veterans and servicemembers, and report back to Congress within 180 days on safety, feasibility, and whether it could be used in military or VA settings. The bill does not authorize psilocybin use itself, but asks DoD to assess whether emerging research might inform future policy for troops and veterans who haven't responded to existing therapies.
Why we flagged it
The bill's core function is to direct DoD to conduct and report on a clinical assessment of emerging PTSD treatments. It is a procedural mandate for evidence review, not a substantive authorization or appropriation.
What the text implies
- The bill references a specific Arizona-sponsored trial (Passage and Fortitude trials) by name, which may signal legislative intent to fast-track review of that particular research pathway rather than a general emerging-treatment framework.
- Coordination with FDA and DEA on Schedule I substance research may create precedent for future psychedelic-assisted therapy pathways in federal healthcare, beyond PTSD.
The full analysis lists 4 implications of this text.
Who stands to gain
Clinical research organizations conducting psilocybin trials; Pharmaceutical/biotech firms developing psychedelic-assisted therapies; Military and VA healthcare infrastructure (if expanded access is implemented)